MEDIAN Announces Two New Project Awards for a total amount of €410,000
MEDIAN Technologies has been selected to manage medical images in two new phase II clinical studies for liver cancer
MEDIAN Technologies (ALMDT), a leading medical imaging software solutions developer and a service provider for image interpretation and management in oncology clinical trials, today announced that it has been selected to provide imaging solutions and services in two phase II clinical trials for Hepatocellular Carcinoma (HCC). These two trials are sponsored by a global biopharmaceutical company.
As part of the projects, imaging data would be acquired in 55 clinical sites based in 5 Asian and 5 European countries. Anticipated total enrollment would be 210 patients with forecasted clinical trial starts in early 2015.
For the first study, MEDIAN will provide imaging services, enabling imaging data collection and quality control. For the second study, MEDIAN will also provide image independent review services performed by radiologists using the MEDIAN LMS platform. MEDIAN LMS is a unique solution for the review of images and quantitative assessment of response to therapy in clinical trials.
The anticipated amount for the two projects, awarded through MEDIAN alliance with its strategic CRO partner, is € 410,000 (eq. $ 554,000).
“We are proud of these new successes in Europe and Asia as it demonstrates the trust our biopharmaceutical clients have in our worldwide operational capabilities” said Nicolas Dano, Director of Business Development Europe and Asia.
Since the beginning of 2013, MEDIAN Technologies has recorded €4.3M (eq. $5.8 M) of orders, including €1,0M of firm orders and €3.3M of project awards*.
[*] A project award notifies a company that their solution has been selected for a given project. A binding contract is then signed within the 18 months following the award, upon confirmation of the upstream clinical results.
About Median Technologies.
Median Technologies develops medical imaging software and services dedicated to oncology clinical trials, cancer screening, and clinical practice. Median Technologies standardizes and automates the interpretation of medical images in oncology to optimize the diagnosis of cancer patients and the assessment of their response to therapy. Median serves two primary markets: drug development and patient care. Median has a strategic partnership with the world’s largest CRO (Contract Research Organization) to offer integrated imaging services for clinical trials to biopharma sponsors worldwide, and a strategic partnership with Canon to develop new imaging technologies, and to address the patient care market.
Founded in 2002, Median Technologies is based in Sophia-Antipolis, France, and has a US subsidiary in Boston. Median has a global reach and actively works with clinical sites located in Asia, Europe, North and South America, and Australia.
Median has received the label “Innovative company” by the BPI and is listed on Euronext Paris’ Alternext market (ISIN: FR0011049824, ticker: ALMDT). The company is eligible for the PEA PME SME equity savings plan setup.
“We are committed to the improvement of cancer patient outcomes through innovation in medical imaging and quality execution for better screening, diagnosis, and monitoring of patients.”